Calamos Advisors LLC Takes $275,000 Position in Inotiv, Inc. (NASDAQ:NOTV)

Calamos Advisors LLC purchased a new position in Inotiv, Inc. (NASDAQ:NOTV - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 66,431 shares of the company's stock, valued at approximately $275,000. Calamos Advisors LLC owned 0.26% of Inotiv at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the business. Vantage Point Financial LLC acquired a new stake in Inotiv in the 4th quarter worth about $1,393,000. KPP Advisory Services LLC boosted its stake in shares of Inotiv by 15.8% in the fourth quarter. KPP Advisory Services LLC now owns 275,267 shares of the company's stock worth $1,140,000 after acquiring an additional 37,549 shares during the last quarter. Thurston Springer Miller Herd & Titak Inc. increased its position in shares of Inotiv by 612.5% during the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 127,257 shares of the company's stock worth $527,000 after purchasing an additional 109,397 shares in the last quarter. Geode Capital Management LLC raised its stake in Inotiv by 7.7% in the 3rd quarter. Geode Capital Management LLC now owns 250,895 shares of the company's stock valued at $427,000 after purchasing an additional 18,039 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in Inotiv by 29.9% in the 2nd quarter. Renaissance Technologies LLC now owns 164,164 shares of the company's stock valued at $273,000 after purchasing an additional 37,800 shares in the last quarter. Hedge funds and other institutional investors own 18.17% of the company's stock.

Insiders Place Their Bets

In related news, Director Michael J. Harrington acquired 10,000 shares of Inotiv stock in a transaction that occurred on Friday, December 6th. The shares were purchased at an average cost of $3.98 per share, for a total transaction of $39,800.00. Following the acquisition, the director now owns 37,500 shares in the company, valued at approximately $149,250. This represents a 36.36 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Robert Jr. Leasure sold 22,700 shares of the company's stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $4.15, for a total transaction of $94,205.00. Following the completion of the transaction, the chief executive officer now directly owns 1,030,209 shares in the company, valued at $4,275,367.35. The trade was a 2.16 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders purchased 71,029 shares of company stock valued at $314,248 and sold 26,872 shares valued at $112,854. Corporate insiders own 7.80% of the company's stock.

Inotiv Trading Down 10.5 %

Shares of Inotiv stock traded down $0.41 during trading hours on Friday, reaching $3.51. 1,090,696 shares of the company's stock were exchanged, compared to its average volume of 575,865. The business has a fifty day moving average of $4.43 and a two-hundred day moving average of $2.82. The company has a debt-to-equity ratio of 2.29, a current ratio of 1.37 and a quick ratio of 1.22. Inotiv, Inc. has a 1 year low of $1.23 and a 1 year high of $11.42.

Inotiv (NASDAQ:NOTV - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The company reported ($0.42) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.10). Inotiv had a negative net margin of 25.40% and a negative return on equity of 15.07%. Equities research analysts predict that Inotiv, Inc. will post -0.73 EPS for the current fiscal year.

Inotiv Company Profile

Inotiv, Inc provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line.